Nexavar posts
Feed
Onyx Pharma (NASDAQ: ONXX) is recently is down $9.23 to $35.70 in pre-open trading.
ONXX and its partner Bayer halted Phase 3 trials of Nexavar and after the company reported a larger than expected Q4 loss.
ONXX overall option implied volatility of 63 is above its 26-week average of 57 according to Track Data, suggesting larger price movement.
Option Update is provided by Stock Specialist Paul Foster of theflyonthewall.com
| # | Blogger | Posts | Cmts |
|---|---|---|---|
| 1 | Joseph Lazzaro | 107 | 0 |
| 2 | Tom Johansmeyer | 98 | 3 |
| 3 | Connie Madon | 50 | 0 |
| 4 | Steven Mallas | 43 | 0 |
| 5 | Mark Fightmaster | 42 | 0 |
| 6 | Tom Taulli | 40 | 0 |
| 7 | Steven Halpern | 31 | 0 |
| 8 | Trey Thoelcke | 29 | 0 |
| 9 | Melly Alazraki | 26 | 0 |
| 10 | Zac Bissonnette | 24 | 0 |
| 11 | Paul Foster | 24 | 0 |
| 12 | Brian White | 22 | 0 |
| 13 | Brent Archer | 21 | 0 |
| 14 | Jon Ogg | 21 | 0 |
| 15 | Jim Cramer | 21 | 0 |
| 16 | Elizabeth Harrow | 18 | 0 |
| 17 | Eric Buscemi | 17 | 0 |
| 18 | Sheldon Liber | 13 | 0 |
| 19 | Michael Fowlkes | 8 | 0 |
| 20 | Beth Gaston Moon | 8 | 0 |
Find out why more people track their portfolios on AOL Money & Finance then anywhere else.
Closing Bell: Dubai sends jitters throughout the market (S, BBY)
Heinz looking good after the second quarter?
Why isn't Bank of America updating its shareholders on CEO situation?